Notice for International Patients & Caregivers
English summary does not mean the trial enrolls international patients. Multiple myeloma interventional clinical trials in China typically require valid Chinese resident identity/national healthcare insurance and strict adherence to China's Human Genetic Resources Administration regulations.
Therapy Focus
Snapshot: 2026-10-21
Oral Small-Molecule Agents Active Trials in China
As of 2026-10-21, there are 11 active clinical trials investigating Oral Small-Molecule Agents for multiple myeloma across 26 provinces and 117 study centers in China. Oral small-molecule agents span CELMoD degraders, BCL-2 inhibitors and HDAC inhibitors. Their oral route suits long-term administration, and they are typically combined with antibodies or immunomodulators to switch mechanism after resistance.
Active Trials
11
Provinces
26
Centers
117
Active Studies (11)
Population synthesized by CMDNShowing 11 published English records of 11 registry trials.
Phase Ib/IIaCTR20241633
RecruitingAn Open-label, Parallel-controlled, Multicenter Phase Ib/IIa Clinical Study on the Efficacy and Safety of Puyistat Mesylate for Injection Combined with Pomalidomide Capsules and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: Small-molecule chemosensitizer (HDAC inhibitor)
Study Sites: West China Hospital of Sichuan University、Peking University People's Hospital、Henan Cancer Hospital、The First Affiliated Hospital, Zhejiang University School of Medicine 等 11 家中心
Phase I/IIaCTR20223160
RecruitingA Multicenter, Non-Randomized, Open-Label Phase I/IIa Clinical Study Evaluating the Safety, Tolerability, and Efficacy of ICP-490 Monotherapy and in Combination with Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: Oral small-molecule "molecular glue" degrader
Study Sites: Peking University People's Hospital、Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine、Shengjing Hospital of China Medical University、Henan Cancer Hospital 等 6 家中心
Phase IICTR20202322
RecruitingAn Open-Label, Single-Arm Phase II Clinical Study Evaluating CX13-608 in Participants with Relapsed or Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: Small molecule targeted drug
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Renji Hospital, Shanghai Jiao Tong University School of Medicine、The First Affiliated Hospital, Zhejiang University School of Medicine、Peking University Third Hospital 等 10 家中心
Phase IIICTR20223338
RecruitingA Phase 3, 2-Stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-1
Target Population: Relapsed/refractory
Target: Next-generation "molecular glue" degrader (CELMoD)
Study Sites: Beijing Chao-Yang Hospital, Capital Medical University (East Campus)、Xi'an International Medical Center Co., Ltd.、Peking University First Hospital、Beijing Chao-Yang Hospital, Capital Medical University (West Campus) 等 32 家中心
Phase ICTR20241210
RecruitingA Multicenter, Open-Label Phase I Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of HMPL-506 in Hematologic Malignancies
Target Population: Relapsed/refractory
Target: Small molecule targeted drug
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Nanfang Hospital of Southern Medical University、Qilu Hospital of Shandong University、Shengjing Hospital of China Medical University 等 13 家中心
Phase I/IICTR20254042
RecruitingA Phase I/II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of HP-001 Capsules Combined with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: Small-molecule chemical drug
Study Sites: West China Hospital, Sichuan University、Henan Cancer Hospital、Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、The First Affiliated Hospital, Zhejiang University School of Medicine 等 20 家中心
Phase ICTR20221007
RecruitingA Phase I Clinical Trial of HRS-3738 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma and Multiple Myeloma
Target Population: Relapsed/refractory
Target: Small molecule oral targeted drug / Next-generation EED (embryonic ectoderm development protein) inhibitor
Study Sites: The First Affiliated Hospital, Zhejiang University School of Medicine、Shengjing Hospital of China Medical University、Henan Cancer Hospital、Shanxi Province Cancer Hospital 等 37 家中心
Phase IIICTR20232917
RecruitingA Two-Stage, Randomized, Multicenter, Controlled, Open-Label, Phase III Study Comparing Iberdomide Maintenance Therapy with Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM)
Target Population: Newly diagnosed/Maintenance
Target: Oral small-molecule "molecular glue" degrader (next-generation Cereblon E3 ligase modulator [CELMoD])
Study Sites: Peking University People's Hospital、Tongji Medical College of Huazhong University of Science and Technology、Qilu Hospital of Shandong University、Jiangsu Province Hospital 等 37 家中心
Phase ICTR20233717
RecruitingA Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of GLB-002 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Target Population: Relapsed/refractory
Target: Molecular glue degrader
Study Sites: Peking University Cancer Hospital、Henan Cancer Hospital、Jiangxi Cancer Hospital、Tianjin Medical University Cancer Institute and Hospital 等 13 家中心
Phase 3CTR20200081
RecruitingA Phase 3, Multicenter, Randomized, Open-Label Study Comparing Venetoclax Plus Dexamethasone Versus Pomalidomide Plus Dexamethasone in Participants with t(11;14)-Positive Relapsed or Refractory Multiple Myeloma
Target Population: Relapsed/refractory
Target: Oral small molecule targeted drug (BCL-2 inhibitor)
Study Sites: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences、Guangdong Provincial People's Hospital、The First Affiliated Hospital of Soochow University、Peking Union Medical College Hospital 等 19 家中心
Phase ICTR20242943
RecruitingA Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of HP-001 Capsules in Patients with Relapsed/Refractory Multiple Myeloma and Non-Hodgkin Lymphoma
Target Population: Relapsed/refractory
Target: Small-molecule chemical drug
Study Sites: West China Hospital, Sichuan University、Henan Cancer Hospital、The First Affiliated Hospital of Nanchang University、Anhui Provincial Cancer Hospital 等 26 家中心